What is Excellergy?
Excellergy is a biotechnology company dedicated to creating a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs). These inhibitors are designed to combat severe allergic diseases, addressing a critical unmet need in patient care. The company's scientific approach aims to significantly improve the quality of life for individuals suffering from debilitating allergic conditions.
How much funding has Excellergy raised?
Excellergy has raised a total of $70M across 1 funding round:
Series A
$70M
Series A (2025): $70M with participation from Samsara BioCapital, Red Tree Venture Capital, and Decheng Capital
Key Investors in Excellergy
Samsara BioCapital
Samsara BioCapital is a venture capital firm dedicated to creating transformative therapeutics. They partner with innovators to support breakthroughs in the biopharmaceutical sector, focusing on healthcare and biotechnology industries.
Red Tree Venture Capital
Red Tree Venture Capital is a San Francisco Bay Area-based firm that invests in transformative life sciences companies. They focus on the discovery, development, and commercialization of innovative therapeutics and medical technologies.
Decheng Capital
Decheng Capital is a global investment firm specializing in early-stage life science and growth-stage healthcare companies. They provide capital and strategic support, aiming to build leading companies through revolutionary technologies.
What's next for Excellergy?
With the recent major strategic investment, Excellergy is poised to accelerate its development pipeline and potentially scale its operations. This Series A financing indicates a transition from early-stage development to a growth phase, likely focusing on advancing its ECRI candidates through clinical trials and preparing for broader market entry. The backing from prominent life sciences investors suggests confidence in Excellergy's technology and its potential to disrupt the treatment landscape for allergic diseases.
See full Excellergy company page
